insights_auto
Nega CRSP oshdi 3,11%?
Batafsil oʻrganishchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
50,07 US$
arrow_upward
+3,11%(+1,51) 1K
49,35 US$
arrow_downward
-1,44% (-0,72)bedtimeYopilgandan keyin
Savdolar yopilgan: 6-noy, 16:00:01 (GMT-5) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoCRSP tikeri uchun statistika yaratilmoqda...
Ochish
48,98 US$
Yuqori
50,27 US$
Past
48,41 US$
Bozor kapitali
4,86 mlrd
Oʻrtacha hajm
1,46 mln
Hajmi
1,24 mln
52 haftalik eng yuqori
63,45 US$
52 haftalik eng past
44,12 US$
Aksiya boʻyicha daromad
-4,75 US$
Beta
1,49
Muomaladagi aksiyalar
97,00 mln
Xodimlar soni
393
Ochish
48,98 US$
Yuqori
50,27 US$
Past
48,41 US$
Bozor kapitali
4,86 mlrd
Oʻrtacha hajm
1,46 mln
Hajmi
1,24 mln
52 haftalik eng yuqori
63,45 US$
52 haftalik eng past
44,12 US$
Aksiya boʻyicha daromad
-4,75 US$
Beta
1,49
Muomaladagi aksiyalar
97,00 mln
Xodimlar soni
393
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Crispr Therapeutics AG haqida
CEOSamarth Kulkarni
Xodimlar soni393
Asos solingan2013
Bosh ofislarZug, Zug, Shveytsariya
SektorHealth Care
Soha-
Veb-saytcrisprtx.com